Welcome to OMGEN

‘Overcoming barriers to commercialisation of ATMPs’ panel at the European Society of Gene and Cell Therapy (ESGCT) 29th Congress in Edinburgh

Closing the gap between innovation and access in rare disease and gene therapy

OMGEN helps life sciences organisations turn breakthrough science into real-world impact — combining deep commercial expertise, market access insight, and organisational change to deliver results where it matters most.

Our comprehensive approach encompasses: